Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, May 27, 2024 for the Memorial Day holiday. Have a healthy, happy holiday.


Demyelinating disorders, including NMOSD, MOG, and MS

Differential diagnosis is critical for appropriate treatment

Neuromyelitis optica spectrum disorder (NMOSD) is an immune-mediated, chronic, and often relapsing inflammatory disease that predominantly affects the optic nerve and spinal cord. It can sometimes be mistaken for multiple sclerosis (MS), which is a disease that affects the central nervous system. Myelin oligodendrocyte glycoprotein (MOG) is an antibody that may be present in NMOSD and other autoimmune disorders. 

Diagnosis is critical because treatments for MS may be ineffective or harmful for patients with NMOSD1

Why order demyelinating disease testing from Quest


1. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-481.  doi:10.1212/WNL.0000000000000101

2. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276-283. doi:10.1001/jamaneurol.2013.5857

3. Kezuka T, Usui Y, Yamakawa N, et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol. 2012;32(2):107-110. doi:10.1097/WNO.0b013e31823c9b6c

4. Waters P, Woodhall M, O’Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e89.doi:10.1212/NXI.0000000000000089 

Join our email community

Get the very latest news and information from Quest Advanced® Neurology.

Sign up